Current situation analysis of diabetic home care patients

Meltem Sertbas, Ozlem Guduk, Ozden Guduk, Zeynep Yazici, Selma Dagci, Yasar Sertbas, Meltem Sertbas, Ozlem Guduk, Ozden Guduk, Zeynep Yazici, Selma Dagci, Yasar Sertbas

Abstract

Objective: Diabetes is one of the primary diagnoses for admission to home health care units. Although there are many studies about elderly diabetic patients, there are not many studies on home care patients with diabetes. The present study aims to analyze the current status of diabetic home care patients with their biochemical data and medications.

Methods: This was a retrospective study, including 256 diabetic patients who were following up by the Home Health Unit of Istanbul Provincial Health Directorate Public Hospitals Services-2. In this study, we analyzed the current biochemical data of the patients with their medications.

Results: In this study, 185 female (72.3%) and 71 male (27.7%) patients were recruited with the mean HbA1c of 8.25±1.77. Among these patients, 65% of them were using oral antidiabetic (OAD), and 58% were using insulin. There were 21 (8.2%) patients who were not receiving any treatment. While patients who were using only oral antidiabetic have better A1c levels (A1c: 7.73±1.45), patients who were insülin using had HbA1c levels as high as the patients who were not using any medication. This may be due to the progression of diabetes, fear of hypoglycemia or insufficient insülin use. While metformin was the most commonly used OAD, with a 38% usage rate. When compared to HbA1c levels, there was no difference between the types of insulin used (p=0.167).

Conclusion: As a result, it is important to plan regular visits and personalized treatment by keeping in mind the benefits to risk ratios in home-care diabetic patients.

Keywords: Antidiabetics; diabetes mellitus; home care services.

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

Copyright: © 2020 by Istanbul Northern Anatolian Association of Public Hospitals.

References

    1. Ünal B, Ergör G, Horasan GD, Kalaça S, Sözmen K. Türkiye kronik hastalıklar ve risk faktörleri sıklığıçalışması. Sağlık BakanlığıYayın No:909. [Accessed Mar 17 2020]. Available at: .
    1. Raghupathi W, Raghupathi V. An Empirical Study of Chronic Diseases in the United States:A Visual Analytics Approach. Int J Environ Res Public Health. 2018;15:431.
    1. Jaul E, Barron J. Age-Related Diseases and Clinical and Public Health Implications for the 85?Years Old and Over Population. Front Public Health. 2017;5:335.
    1. Umpierrez GE, Pasquel FJ. Management of Inpatient Hyperglycemia and Diabetes in Older Adults. Diabetes Care. 2017;40:509–17.
    1. American Diabetes Association 11 Older Adults:Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;4:S119–25.
    1. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650–64.
    1. Satman İ, İmamoğlu Ş, Yılmaz CS, Ayvaz G, Çömlekçi A. Türkiye'de ve Dünya'da diyabet, Türkiye Endokrinoloji ve Metabolizma Derneği Diabetes Mellitus Çalışma ve Eğitim Grubu Raporu. Turkish Journal of Endocrinology and Metabolism. 2012;16
    1. Directive on the Procedures and Principles of Home Health Care Services Provided by the Ministry of Health 2010. [Accessed Mar 17 2020]. Available at: .
    1. O'Reilly CA. Managing the care of patients with Diabetes in the Home Care Setting. Diabetes Spectrum. 2005;18:162–6.
    1. Subasi N, Oztek Z. Türkiyede karşılanamayan bir gereksinim:Evde bakım hizmeti. TSK Koruyucu Hekimlik Bülteni. 2006;5:19–31.
    1. İsik O, Kandemir A, Erisen MA, Fidan C. Evde sağlık hizmeti alan hastaların profili ve sunulan hizmetin değerlendirilmesi. Hacettepe Sağlık İdaresi Dergisi. 2016;19:171–86.
    1. American Diabetes Association 6 Glycemic Targets:Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S61–70.
    1. American Diabetes Association 12 Older Adults:Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S139–47.
    1. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients:the diabetes and aging study. Diabetes Care. 2011;34:1329–36.
    1. Hamada S, Gulliford MC. Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol. J Am Geriatr Soc. 2016;64:1425–31.
    1. International Diabetes Federation Managing older people with type 2 diabetes global guideline. Brussels, Belgium:International Diabetes Federation (IDF) 2013. [Accessed Mar 17 2020]. Available at: .
    1. Diabetes Canada Clinical Practice Guidelines Expert Committee. Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes in Older People. Can J Diabetes. 2018;42(Suppl 1):S283–95.
    1. Patel B, Oza B, Patel KP, Malhotra SD, Patel VJ. Pattern of antidiabetic drugs use in type-2 diabetic patients in a medicine outpatient clinic of a tertiary care teaching hospital. International Journal of Basic &Clinical Pharmacology. 2013;2:485–91.
    1. Kannan Arshad. Kumar S. A study on drug utilization of oral hypoglycemic agents in type-2 diabetic patients. Asian Journal of Pharmaceutical and Clinical Research. 2011;4:60–4.
    1. LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults:An Endocrine Society*Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1520–74.
    1. Kezerle L, Shalev L, Barski L. Treating the elderly diabetic patient:special considerations. Diabetes Metab Syndr Obes. 2014;7:391–400.
    1. Bajwa SJ, Sehgal V, Kalra S, Baruah MP. Management of diabetes mellitus type-2 in the geriatric population:Current perspectives. J Pharm Bioallied Sci. 2014;6:151–7.
    1. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–9.
    1. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–4.
    1. Sertbas M, Sertbas Y, Ordu O, Berber E, Ozen B, Ozdemir A. Myocardial injury and acute renal failure associated with lactic acidosis due to suicide attempt with metformin. J Pak Med Assoc. 2016;66:223–5.
    1. de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency:randomised placebo controlled trial Version 2. BMJ. 2010;340:c2181.
    1. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–18.
    1. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129–37.
    1. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes:a meta-analysis. CMAJ. 2012;184:E675–83.
    1. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors:a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2007;41:51–60.
    1. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, et al. TECOS Study Group. Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care. 2017;40:164–70.
    1. Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus:a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther. 2010;32:1188–204.
    1. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
    1. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–4.
    1. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.
    1. Koliaki C, Doupis J. Incretin-based therapy:a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2:101–21.
    1. Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age:a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011;9:423–33.
    1. Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, et al. GetGoal-O Trial Investigators. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment:The GetGoal-O Randomized Trial. Diabetes Care. 2017;40:485–93.
    1. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes 2018 A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2018;41:2669–701.
    1. Ünlüsoy MC, Akuç S, İnceli Hİ. SGLT2 Inhibitors in the Treatment of Diabetes. FABAD J Pharm Sci. 2018;43:157–70.
    1. Elmore LK, Baggett S, Kyle JA, Skelley JW. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Consult Pharm. 2014;29:335–46.
    1. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus:a randomized trial. Hosp Pract (1995) 2013;41:72–84.
    1. International Diabetes Federation Guideline Development Group Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1–52.
    1. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract. 2004;66:23–9.
    1. Galic E, Vrtovec M, Bozikov V, Schwarzenhofer M, Milicevic Z. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. Med Sci Monit. 2005;11:PI87–92.
    1. Khamseh ME, Haddad J, Yang W, Zilov A, Bech OM, Hasan MI. Safety and effectiveness of biphasic insulin aspart 30 in different age-groups:a1chieve sub-analysis. Diabetes Ther. 2013;4:347–61.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe